Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases.

Breast cancer research : BCR - 30 Nov 2020

Leone Jose Pablo, Emblem Kyrre E, Weitz Michelle, Gelman Rebecca S, Schneider Bryan P, Freedman Rachel A, Younger Jerry, Pinho Marco C, Sorensen A Gregory, Gerstner Elizabeth R, Harris Gordon, Krop Ian E, Morganstern Daniel, Sohl Jessica, Hu Jiani, Kasparian Elizabeth, Winer Eric P, Lin Nancy U

Abstract excerpt

BACKGROUND: We aimed to examine the safety and efficacy of bevacizumab and carboplatin in patients with breast cancer brain metastases. METHODS: We enrolled patients with breast cancer and > 1 measurable new or progressive brain metastasis. Patients received bevacizumab 15 mg/kg intravenously (IV) on cycle 1 day 1 and carboplatin IV AUC = 5 on cycle 1 day 8. Patients with HER2-positive disease also received...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Bevacizumab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast

Share to Carboplatin

Share to Kaplan-Meier Estimate

Share to Progression-Free Survival

Share to Trastuzumab

Share to Vascular Endothelial Growth Factor A

Source

Open in PubMed Open full text

Identifiers

PMID: 33256829
DOI: 10.1186/s13058-020-01372-w
PMCID: PMC7706261

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases.PMID 33256829Read ↗

LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.Semantic proximity Read ↗

Identification of targetable genomic profiling of breast cancer brain metastases identifies alterations and genomic signatures relevant to immune-checkpoint and PARP inhibitorsSemantic proximity Read ↗

Clinical and molecular features of resected breast cancer brain metastases: a single center retrospective cohort study.Semantic proximity Read ↗

Targetable genomic profiling of breast cancer brain metastases identifies alterations and genomic signatures relevant to immune-checkpoint and PARP inhibitorsSemantic proximity Read ↗

Breast cancer brain metastases genomic profiling identifies alterations targetable by immune-checkpoint and PARP inhibitorsSemantic proximity Read ↗

Molecular subtyping of brain metastases and implications for therapy.Semantic proximity Read ↗

Abemaciclib plus fulvestrant for the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer with cystic brain metastases: a case report and literature reviewSemantic proximity Read ↗

Prolonged survival in a HER2 positive metastatic breast cancer patient with brain metastases treated with TDM1 after failure of next generation HER2 targeted therapiesSemantic proximity Read ↗

Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer.Semantic proximity Read ↗

BRCA1 Mutations Associated With Increased Risk of Brain Metastases in Breast Cancer: A 1: 2 Matched-pair Analysis.Semantic proximity Read ↗

Analysis of Breast Cancer Brain Metastases Reveals an Enrichment of Cyclin-Dependent Kinase 12 Structural Rearrangements in Human Epidermal Growth Factor Receptor 2–Positive DiseaseSemantic proximity Read ↗

Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non-Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical Trials.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.